Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Angiotensin A

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Angiotensin A is a potent endogenous vasoconstrictor octapeptide. It is a derivative of angiotensin II (Ang II) that differs from Ang II in having alanine instead of aspartic acid as the first amino acid. It shows similar affinity for AT1 and AT2 receptors as angiotensin II with Ki values of 1.6 and 2.3 nM in vitro. It causes pressor and renal vasoconstrictor effects in rodents by the AT1 receptor. It is inhibited by Candesartan but not by AT2 receptor ligands in vivo. It also increases inositol phosphate accumulation with a similar potency to Ang II with EC50 value of 6.7 nM.

Category

Peptide Inhibitors

Catalog number

BAT-015367

CAS number

51833-76-2

Molecular Formula

C49H71N13O10

Molecular Weight

1002.18

Size	Price	Stock	Quantity
10 mg	$299	In stock
100 mg	$499	In stock

Specification
Reference Reading

IUPAC Name

(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid

Synonyms

Ala-Angiotensin III; H-Ala-Arg-Val-Tyr-Ile-His-Pro-Phe-OH; Ang A; Angiotensin II, 1-L-alanine-5-L-isoleucine-; L-alanyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine

Appearance

White Powder

Purity

≥95%

Density

1.4±0.1 g/cm3

Sequence

ARVYIHPF

Storage

Store at -20°C

Solubility

Soluble in Water

InChI

InChI=1S/C49H71N13O10/c1-6-28(4)40(46(69)58-36(24-32-25-53-26-55-32)47(70)62-21-11-15-38(62)44(67)59-37(48(71)72)23-30-12-8-7-9-13-30)61-43(66)35(22-31-16-18-33(63)19-17-31)57-45(68)39(27(2)3)60-42(65)34(56-41(64)29(5)50)14-10-20-54-49(51)52/h7-9,12-13,16-19,25-29,34-40,63H,6,10-11,14-15,20-24,50H2,1-5H3,(H,53,55)(H,56,64)(H,57,68)(H,58,69)(H,59,67)(H,60,65)(H,61,66)(H,71,72)(H4,51,52,54)/t28-,29-,34-,35-,36-,37-,38-,39-,40-/m0/s1

InChI Key

CHCOFDZSJYMQMX-NOQNJSOHSA-N

Canonical SMILES

CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)N

1.Cardiovascular effects of angiotensin A: a novel peptide of the renin-angiotensin system.

Coutinho DC1, Foureaux G1, Rodrigues KD1, Salles RL1, Moraes PL1, Murça TM1, De Maria ML1, Gomes ER2, Santos RA2, Guatimosim S2, Ferreira AJ3. J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):480-6. doi: 10.1177/1470320312474856. Epub 2013 Feb 5.

INTRODUCTION: Angiotensin (Ang) A was first identified in human plasma and it differs from Ang II in Ala(1) instead of Asp(1). Here, we hypothesized that the actions of this peptide might explain, at least partially, the limited effects of AT1R antagonists in certain cardiovascular diseases.

2.Reduction of angiotensin A and alamandine vasoactivity in the rabbit model of atherogenesis: differential effects of alamandine and Ang(1-7).

Habiyakare B1, Alsaadon H, Mathai ML, Hayes A, Zulli A. Int J Exp Pathol. 2014 Aug;95(4):290-5. doi: 10.1111/iep.12087. Epub 2014 Jun 20.

Novel treatments are necessary to reduce the burden of cardiovascular disease (CVD). Alamandine binds to MrgD and is reported to induce vasodilation via stimulation of endothelial nitric oxide synthase (eNOS), but its role in atherogenic blood vessels is yet to be determined. To determine the vasoactive role of alamandine and its precursor AngA in diseased aorta, New Zealand White rabbits were fed a diet containing 1% methionine + 0.5% cholesterol + 5% peanut oil for 4 weeks (MC, n = 5) or control (n = 6). In abdominal aorta, alamandine (1 μM) was added 30 min before a dose-response curve to angiotensin II or AngA (1 nM-1 μM), and immunohistochemistry was used to identify MrgD receptors and eNOS. The thoracic aorta, renal, carotid and iliac arteries were mounted in organ baths. Rings were precontracted with phenylephrine, then a bolus dose of alamandine (1 μM) was added 10 min before a dose-response curve to acetylcholine (0.01 μM-10 μM).